Current treatment of hepatitis C;Tratamiento actual de la hepatitis C crónica

Gastroenterologia y Hepatologia

Volumn 24, Issue SUPPL. 1, 2001, Pages 51-57

  Rodriguez M ^a   Perez R ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; CONFERENCE PAPER; CONVULSION; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSOMNIA; IRRITABILITY; LEUKOPENIA; RASH; THROMBOCYTOPENIA; TREATMENT PLANNING;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; RIBAVIRIN; RNA, VIRAL;

EID: 17944403241     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Hepatitis C: Clinical spectrum of the disease
2. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon: A preliminary report
3. National Institutes of Health Consensus Development Conference Panel Statement management of hepatitis C
4. Ribavirin treatment for chronic hepatitis C
5. Ribavirin as therapy for chronic hepatitis C. A randomised, double-blind, placebo-controlled trial
6. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
7. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C
8. Randomised, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C
9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
10. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
12. International Consensus Conference on hepatitis C
13. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
14. Transforming growth factor β1 and α in chronic liver disease: Effects of interferon alpha therapy
15. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
16. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
17. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
18. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
19. High dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential
20. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
21. 10-Year follow-up after interferon-alfa therapy for chronic hepatitis C
22. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
23. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
24. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
25. Hepatitis C virus infection: Quality of live and side effects
26. A survey of adverse events in 11.241 patients with chronic viral hepatitis treated with alfa interferon
27. The metabolism of ribavirin in erytrocytes and nucleated cells
28. Pharmacokinetics of ribavirine and urinary excretion of the major metabolite 1.2.4-triazole-3-carboxamide in normal volunteers
29. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C
30. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels
31. Outcome of hepatitis C in blood donors and asymptomatic outpatients: An eight-year follow-up study
32. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison of hepatic histology and response to interferon therapy
33. Prospective study of progression of fibrosis in untreated patients with mild chronic hepatitis C
34. Watchful waiting with periodic liver biopsy versus inmediate empirical therapy for histologically mild chronic hepatitis C
35. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
36. Standarization of hepatits C virus RNA quantification
37. Is an "a la carte" combination interferon alfa 2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
38. À la carte interferon for hepatitis C?
39. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characterstics: A comparison
40. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
41. Predicting response to initial therapy with interferon alfa during ribavirin in chronic hepatitis C using serum HCV RNA during therapy
42. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
43. Better efficacy of a 12-month interferon alpha-2b retreatment in patients with chronic hepatitis C relapsing after a 6 month treatment: A multicenter, controlled, randomized trial
44. Retreatment of chronic hepatitis C with Consensus interferon
45. Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 to 12 months
46. Hepatitis C virus resistance to antiviral therapy
47. Therapy of hepatitis C: Re-treatment with alpha-interferon
48. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers
49. Interferon alpha-2b/ribavirin in both high and standard dose induces sustained response in previous interferon monotherapy non-responders
50. Sustained response with interferon-A (IFN) induction dosing and ribavirin in IFN non-responders (NR) with chronic hepatitis C (CHC)
51. Triple antiviral therapy as a new option for patients with interferon non-responsive chronic hepatitis C
52. Evaluation of the safety and efficacy of once-weekly Peginterferon alfa-2a in patients with chronic hepatitis C
53. Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C
54. PEG-interferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 Week treatment analysis of a multicenter, multinational phase III randomized controlled trial